-
1
-
-
79953295767
-
European cancer mortality predictions for the year 2011
-
Malvezzi M, Arfé A, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2011. Ann Oncol. 2011;22:947-56.
-
(2011)
Ann Oncol.
, vol.22
, pp. 947-956
-
-
Malvezzi, M.1
Arfé, A.2
Bertuccio, P.3
Levi, F.4
la Vecchia, C.5
Negri, E.6
-
2
-
-
80053238941
-
Delivering affordable cancer care in high-income countries
-
Sullivan R, Peppercorn J, Sikora K et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933-80.
-
(2011)
Lancet Oncol.
, vol.12
, Issue.10
, pp. 933-980
-
-
Sullivan, R.1
Peppercorn, J.2
Sikora, K.3
-
3
-
-
84864367909
-
Global cancer transitions according to the Human Development Index (2008-2030): A population-based study
-
Aug, doi: 10.1016/S1470-2045(12)70211-5
-
Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012 Aug;13(8):790-801. doi: 10.1016/S1470-2045(12)70211-5.
-
(2012)
Lancet Oncol.
, vol.13
, Issue.8
, pp. 790-801
-
-
Bray, F.1
Jemal, A.2
Grey, N.3
Ferlay, J.4
Forman, D.5
-
4
-
-
44949192861
-
Making progress against cancer in Europe in 2008
-
Albreht T, McKee M, Alexe DM, Coleman MP, Martin-Moreno JM. Making progress against cancer in Europe in 2008. Eur J Cancer. 2008;44:1451-6.
-
(2008)
Eur J Cancer.
, vol.44
, pp. 1451-1456
-
-
Albreht, T.1
McKee, M.2
Alexe, D.M.3
Coleman, M.P.4
Martin-Moreno, J.M.5
-
6
-
-
81355158511
-
Time to consider cost in evaluating cancer drugs in United States?
-
14 July, [cited 2012 Aug 26]. Available from
-
Mulcahy N. Time to consider cost in evaluating cancer drugs in United States? Medscape News, 14 July 2009 [cited 2012 Aug 26]. Available from: http://www.medscape.com/viewarticle/705689
-
(2009)
Medscape News
-
-
Mulcahy, N.1
-
7
-
-
79959653044
-
Therapeutic decision making in oncology
-
Perrin S. Therapeutic decision making in oncology. Hosp Pharm Europe. 2010; 52:36-7.
-
(2010)
Hosp Pharm Europe.
, vol.52
, pp. 36-37
-
-
Perrin, S.1
-
8
-
-
80051490700
-
Biosimilars: Are they ready for primetime in the United States?
-
Hirsch BR, Lyman GH. Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw. 2011;9(8):934-3.
-
(2011)
J Natl Compr Canc Netw.
, vol.9
, Issue.8
, pp. 934-943
-
-
Hirsch, B.R.1
Lyman, G.H.2
-
10
-
-
33846974021
-
Cost of cancer care: Issues and implications
-
Meropol NJ, Schulman KA. Cost of cancer care: issues and implications. J Clin Oncol. 2007;10:180-6.
-
(2007)
J Clin Oncol.
, vol.10
, pp. 180-186
-
-
Meropol, N.J.1
Schulman, K.A.2
-
11
-
-
80051984166
-
Biosimilars of biological drug therapies: Regulatory, clinical and commercial considerations
-
Dranitsaris G, Amir E, Dorward K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs. 2011;71:1527-36.
-
(2011)
Drugs.
, vol.71
, pp. 1527-1536
-
-
Dranitsaris, G.1
Amir, E.2
Dorward, K.3
-
12
-
-
79952973241
-
Biosimilar medicines and cost-effectiveness
-
Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29-36.
-
(2011)
Clinicoecon Outcomes Res.
, vol.3
, pp. 29-36
-
-
Simoens, S.1
-
13
-
-
79952923217
-
The future of biosimilars
-
Mellstedt H. The future of biosimilars. Hosp Pharm Europe. 2010;49:33-4.
-
(2010)
Hosp Pharm Europe.
, vol.49
, pp. 33-34
-
-
Mellstedt, H.1
-
16
-
-
84871355839
-
Comparative cost-effectiveness across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia
-
Aapro M, Cornes P, Abraham I. Comparative cost-effectiveness across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Practice. 2012;18:171-9.
-
(2012)
J Oncol Pharm Practice.
, vol.18
, pp. 171-179
-
-
Aapro, M.1
Cornes, P.2
Abraham, I.3
-
17
-
-
84864487642
-
Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer
-
May
-
Aapro M, Cornes P, Sun D, Abraham I. Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer. Ther Adv Med Oncol. 2012 May;4(3):95-105.
-
(2012)
Ther Adv Med Oncol.
, vol.4
, Issue.3
, pp. 95-105
-
-
Aapro, M.1
Cornes, P.2
Sun, D.3
Abraham, I.4
-
18
-
-
84876455323
-
Biosimilar medicines in oncology: Single-center experience with biosimilar G-CSF
-
Salesi N, Di Cocco B, Veltri E. Biosimilar medicines in oncology: single-center experience with biosimilar G-CSF. J Clin Oncol. 2012;30(suppl):abstr e19501.
-
(2012)
J Clin Oncol.
, vol.30
, Issue.SUPPL.
-
-
Salesi, N.1
Di Cocco, B.2
Veltri, E.3
-
19
-
-
84857903642
-
What do prescribers think of biosimilars?
-
Aapro M. What do prescribers think of biosimilars? Target Oncol. 2012;7 Suppl 1:S51-S55.
-
(2012)
Target Oncol.
, vol.7
, Issue.SUPPL. 1
-
-
Aapro, M.1
-
20
-
-
81355123577
-
Biosimilars: What they are and their use in oncology
-
Grande E, Carrato A. Biosimilars: what they are and their use in oncology. Cancer Chemother Rev. 2011;6:23-30.
-
(2011)
Cancer Chemother Rev.
, vol.6
, pp. 23-30
-
-
Grande, E.1
Carrato, A.2
-
21
-
-
84857905655
-
The economic pressures for biosimilar drug use in cancer medicine
-
Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012 7 Suppl 1:S57-S67
-
(2012)
Target Oncol.
, vol.7
, Issue.SUPPL. 1
-
-
Cornes, P.1
-
22
-
-
78751635955
-
-
European Medicines Agency, London, UK: [cited 2012 Aug 26]. Available from
-
European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies. London, UK: 2010 [cited 2012 Aug 26]. Available from: http://www.ema.europa.eu/ docs/en_GB/document_library/Scientific_guideline/2010/11/WC500 099361.pdf
-
(2010)
Guideline on similar biological medicinal products containing monoclonal antibodies
-
-
|